Table 2. Tail Intensity (% tail DNA) and cell viability (expressed as % in relation to saline solution group) in cells of kidney and peripheral blood after subacute treatment with CMN SD, unmodified CMN, cDDP and their associations, analyzed in the comet assay.
| Treatments | % tail DNA | Cell viability (%) | ||
|---|---|---|---|---|
| Kidney | Peripheral blood | Kidney | Peripheral blood | |
| Saline solution | 7.4 ± 4.0 | 4.4 ± 2.1 | 100.0 ± 0.0 | 100.0 ± 0.0 |
| GLA | 8.3 ± 2.9 | 2.6 ± 0.7 | 88.5 ± 1.9 | 98.8 ± 0.7 |
| CMN SD 5 | 9.4 ± 2.8 | 4.7 ± 1.6 | 91.2 ± 2.4 | 99.2 ± 0.7 |
| CMN SD 25 | 6.7 ± 1.7 | 4.8 ± 0.6 | 88.0 ± 2.6 | 98.7 ± 0.5 |
| CMN SD 50 | 7.5 ± 3.0 | 2.1 ± 1.1 | 88.5 ± 3.3 | 99.0 ± 0.6 |
| CMN 50 | 5.5 ± 2.8 | 3.2 ± 0.9 | 89.0 ± 2.3 | 98.7 ± 0.5 |
| cDDP | 3.4 ± 1.1* | 2.5 ± 0.4 | 89.7 ± 1.7 | 99.2 ± 0.7 |
| GLA + cDDP | 3.8 ± 0.7* | 2.2 ± 0.8 | 86.5 ± 3.1 | 98.8 ± 0.7 |
| CMN SD 5 + cDDP | 5.0 ± 1.1 | 3.0 ± 1.7 | 90.5 ± 2.5 | 99.8 ± 0.7 |
| CMN SD 25 + cDDP | 6.4 ± 1.1 | 4.4 ± 1.2 | 87.3 ± 3.6 | 98.5 ± 1.2 |
| CMN SD 50 + cDDP | 5.7 ± 1.1 | 3.3 ± 1.5 | 85.5 ± 4.4 | 98.5 ± 1.4 |
| CMN 50 + cDDP | 4.0 ± 0.8 | 2.1 ± 0.6 | 88.5 ± 2.2 | 99.2 ± 0.7 |
Saline solution or cDDP was administered intraperitoneally 30 min after the last gavage of CMN SD or unmodified CMN. %: percentage; cDDP: cisplatin (6 mg/kg b.w.); CMN: curcumin; GLA: gelucire®50-13/aerosil®; SD: solid dispersion. The results represent the mean ± standard deviation for each group (six animals/group).
*
Significantly different from saline solution group, assessed by ANOVA and Tukey’s post hoc test (p < 0.05).